Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

NCT05560308 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy

Interventions

DRUG: Trastuzumab Emtansine for Injection
DRUG: Pyrotinib Maleate Tablets

Sponsor

Tianjin Medical University Cancer Institute and Hospital